Previous 10 | Next 10 |
SAN JOSE, Calif. , June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed D...
Gainers: Sorrento Therapeutics (NASDAQ: SRNE ) +195% . More news on: Sorrento Therapeutics, Inc., Aurora Cannabis Inc., Bridgeline Digital, Inc., Stocks on the move, , Read more ...
Aridis Pharmaceuticals (NASDAQ: ARDS ): Q1 GAAP EPS of -$0.73 misses by $0.19 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN JOSE, Calif. , May 12, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate result...
Gainers: Portola Pharmaceuticals (NASDAQ: PTLA ) +130% . More news on: Portola Pharmaceuticals, Inc., CleanSpark, Inc., Genprex, Inc., Stocks on the move, , Read more ...
Aridis Pharmaceuticals (NASDAQ: ARDS ) enrolls first COVID-19 patient in its ongoing Phase 3 clinical trial of AR-301 , a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical ventilators. More news on: Aridis Pharmaceuticals, Inc., Healthcare ...
SAN JOSE, Calif. , May 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the enrollment of its fir...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN JOSE, Calif. , April 29, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today its participation in M...
Aridis Pharmaceuticals (NASDAQ: ARDS ): Q4 GAAP EPS of -$0.63 beats by $0.17 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aridis Pharmaceuticals Inc. Company Name:
ARDS Stock Symbol:
NASDAQ Market:
Aridis Pharmaceuticals Inc. Website:
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...